Taxane Choice With Pertuzumab/Trastuzumab in HER2+ MBC Does Not Affect Outcome

The combination of pertuzumab and trastuzumab plus paclitaxel is commonly being used in the community for the treatment of patients with HER2-positive breast cancer, and appears to be as effective as pertuzumab and trastuzumab plus docetaxel according to real-world findings from a retrospective cohort study.

Read the full article here

Related Articles